MRNA
Moderna, Inc. · Healthcare
49.09
0.66%(+0.32)
Market OpenLast Updated: — ET
52W L: $22.2852W H: $59.55
$49.11
CHG-1.99 (-3.89%)
H$57.88
L$47.14
VOL127M
MRNA (1h)
Moderna, Inc. · Healthcare
This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined.
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026. Moderna's presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," details an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults 50 years and older following prior seasonal influenza vaccination with mRNA-1010 or a licensed egg-based influenza vaccine.
My previous recommendation of Moderna didn't work out so well, because COVID sales have declined over the last several years. Spikevax 2024 sales reached only $3.1B, and RSV sales were a major disappointment at $25M, failing to offset COVID-19 declines. Despite a 40% YoY revenue drop to $1.9B in 2025, MRNA maintains robust liquidity with $8.1B in cash/investments and a conservative 0.151 debt-to-equity ratio.
In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding trading day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
Mock James M
officer: Chief Financial Officer
1,453 SH @ $0.00
2026-04-02
Mock James M
officer: Chief Financial Officer
703 SH @ $50.03
2026-04-02
Mock James M
officer: Chief Financial Officer
1,453 SH @ $0.00
2026-04-02
Klinger Shannon Thyme
officer: Chief Legal Officer
11,797 SH @ $0.00
2026-03-05
Klinger Shannon Thyme
officer: Chief Legal Officer
11,797 SH @ $0.00
2026-03-05
Klinger Shannon Thyme
officer: Chief Legal Officer
5,704 SH @ $57.80
2026-03-05
Mock James M
officer: Chief Financial Officer
11,797 SH @ $0.00
2026-03-05
Mock James M
officer: Chief Financial Officer
11,797 SH @ $0.00
2026-03-05